Epiomic Epidemiology Series: Autoimmune Haemolytic Anemia Forecast in 8 Major Markets 2016-2026

June 2016 | 48 pages | ID: E047CBB3B5AEN
Black Swan Analysis limited

Abstracts

Autoimmune haemolytic anaemia (AIHA) is an immune disorder caused by auto-antibodies against unmodified autologous red blood cells and can range in presentation from a mild illness to a rapidly fatal severe condition.

This report provides the current incident population for AIHA across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of AIHA’s have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for AIHA include:

• Lymphoproliferative conditions:
  • CLL
  • HL
  • NHL
• Myeloproliferative conditions:
  • Multiple myeloma
  • Myelofibrosis
  • MGUS
• Autoimmune conditions:
  • RA
  • SLE
  • Polyarteritis nodosa
• Infections:
  • Pneumonia & Tuberculosis
  • Syphilis
  • Epstein-Barr
  • Chronic active hepatitis
  • Mononucleosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global AIHA’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the incidence of the subdivided types of AIHA and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on AIHA’s incident population.
• Identify sub-populations within AIHA which require treatment.
• Gain an understanding of the specific markets that have the largest number of AIHA patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Clinical Management of AIHA
  Transfusion therapy in AIHA
Key Co-morbid Conditions/Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Incidence for AIHA
Subtypes of AIHA patients
  Warm AIHA patients
  Cold AIHA patients
  Mixed-type AIHA patients
Market Forecast for AIHA
  1st Line Treatment Options within Warm & Mixed-type AIHA
  2nd Line Treatment Options within Warm & Mixed-type AIHA
  1st Line Treatment Options within Cold AIHA
  2nd Line Treatment Options within Cold AIHA
  Requirement for Blood Transfusions within AIHA
Methodology for Forecast Figures
Abbreviations used in the report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

Drugs implicated in development of AIHA
Tests for AIHA and expected findings in haemolysis
Classification of AIHA
Treatment options for warm AIHA
Treatment options for cold AIHA
Incidence of AIHA, total (000s)
Incidence of AIHA, males (000s)
Incidence of AIHA, females (000s)
Incident AIHA by main sub-type, total (000s)
Incident Warm AIHA by cause, total (000s)
Warm Secondary AIHA by main aetiology, total (000s)
Incident Cold AIHA by main type, total (000s)
Incident CAS AIHA by cause, total (000s)
CAS Secondary AIHA by main aetiology, total (000s)
Incident Mixed-type AIHA by cause, total (000s)
Mixed-type Secondary AIHA by main aetiology, total (000s)
Prednisolone estimated forecast 1st line, Revenue (£000s)
Rituximab estimated forecast 2nd line, Revenue (£000s)
Splenectomy estimated forecast 2nd line, Patients (000s)
Rituximab estimated forecast 1st line, Revenue (£000s)
Rituximab estimated forecast 2nd line, Revenue (£000s)
Transfusion estimated forecast, Patients (000s)
Abbreviations and Acronyms used in the report
USA Incidence of AIHA by 5-yr age cohort, males (000s)
USA Incidence of AIHA by 5-yr age cohort, females (000s)
France Incidence of AIHA by 5-yr age cohort, males (000s)
France Incidence of AIHA by 5-yr age cohort, females (000s)
Germany Incidence of AIHA by 5-yr age cohort, males (000s)
Germany Incidence of AIHA by 5-yr age cohort, females (000s)
Italy Incidence of AIHA by 5-yr age cohort, males (000s)
Italy Incidence of AIHA by 5-yr age cohort, females (000s)
Spain Incidence of AIHA by 5-yr age cohort, males (000s)
Spain Incidence of AIHA by 5-yr age cohort, females (000s)
UK Incidence of AIHA by 5-yr age cohort, males (000s)
UK Incidence of AIHA by 5-yr age cohort, females (000s)
Brazil Incidence of AIHA by 5-yr age cohort, males (000s)
Brazil Incidence of AIHA by 5-yr age cohort, females (000s)
Japan Incidence of AIHA by 5-yr age cohort, males (000s)
Japan Incidence of AIHA by 5-yr age cohort, females (000s)